| Date | Quarter | Session | EPS (est → actual) | Revenue (est → actual) |
|---|---|---|---|---|
| Nov 4, 2026Next | Q3 2026 | — | 1.38 | 1.97 B |
Aug 28, 2026
Solventum’s 22% return over the past six months has outpaced the S&P 500 by 10.4%, and its stock price has climbed to $89.05 per share. This was partly due to its solid quarterly results, and the run-up might have investors contemplating their next move.
Aug 14, 2026
Solventum plans to spin off its $1.4B HIS business, sharpening its MedTech focus while giving HIS more flexibility to pursue growth.
Solventum has underperformed the broader market, while analysts remain moderately optimistic about its future prospects.
Aug 13, 2026
CEO Hanson discusses HIS separation strategy and $2.2B in quarterly sales growth.
Aug 11, 2026
Healthcare solutions provider Solventum (NYSE:SOLV) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 2.2% year on year to $2.21 billion. Its non-GAAP profit of $2.55 per share was 33.8% above analysts’ consensus estimates.
Aug 9, 2026
Solventum’s analyst fair value estimate has been revised from US$82.15 to US$93.15, a shift of about 13% in the updated framework. This adjustment aligns with recent analyst commentary that points to Q2 results, the planned Health Information Systems separation, and views on the company’s MedTech focus as reasons to revisit price targets. Read on to see how these factors shape the evolving Solventum narrative and what to watch as new data comes in. Analyst Price Targets don't always capture...
Solventum (NYSE:SOLV) reported second-quarter results that exceeded its internal expectations, supported by broad-based segment performance, planned order activity ahead of an ERP cutover and a tariff refund benefit. The company also announced plans to separate its Health Information Systems, or HIS
Aug 6, 2026
SOLV's Q2 earnings and revenues beat estimates as organic sales increase 9.5%, prompting higher 2026 guidance despite ERP timing benefits.
UBS analyst Kevin Caliendo maintains Solventum (NYSE:SOLV) with a Buy and raises the price target from $95 to $101.
Piper Sandler analyst Jason Bednar maintains Solventum (NYSE:SOLV) with a Overweight and raises the price target from $92 to $105.
Moby summary of Solventum Corporation's Q2 2026 earnings call
Wedbush analyst Michael Piccolo maintains Solventum (NYSE:SOLV) with a Outperform and raises the price target from $94 to $101.
Keybanc analyst Brett Fishbin maintains Solventum (NYSE:SOLV) with a Overweight and raises the price target from $93 to $102.
Stifel analyst Rick Wise maintains Solventum (NYSE:SOLV) with a Buy and raises the price target from $90 to $100.
The software business needs “a different investment level” to quickly realize its potential, Solventum’s CEO said.
BTIG analyst Ryan Zimmerman maintains Solventum (NYSE:SOLV) with a Buy and raises the price target from $91 to $95.
Solventum Corp (SOLV) beats Q2 expectations with 9.5% organic growth, announces HIS separation, and raises full-year guidance.
Aug 5, 2026
Investing.com -- Solventum Corp (NYSE:SOLV) reported second quarter results that exceeded analyst expectations and raised its full-year guidance, driven by strong organic sales growth across all business segments.
Solventum (SOLV) delivered earnings and revenue surprises of +33.51% and +2.03%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
The headline numbers for Solventum (SOLV) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Healthcare solutions provider Solventum (NYSE:SOLV) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 2.2% year on year to $2.21 billion. Its non-GAAP profit of $2.55 per share was 33.8% above analysts’ consensus estimates.
2026-08-05. The following slide deck was published by Solventum Corporation in conjunction with their 2026 Q2 earnings call.
Solventum Corporation (SOLV) Q2 2026 Earnings Call August 5, 2026 4:30 PM EDTCompany ParticipantsAmy Wakeham - Senior Vice President of Investor Relations...
